Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IONIS-ENaCRx · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| IONIS-ENaCRx | EXPERIMENTAL | Ascending single and multiple doses of IONIS-ENaCRx inhaled or nebulized. |
| Placebo | PLACEBO_COMPARATOR | Placebo comparator calculated volume to match active comparator inhaled or nebulized. |
| Name | Type | Description |
|---|---|---|
| IONIS-ENaCRx | DRUG | Ascending single and multiple doses of IONIS-ENaCRx inhaled or nebulized. |
| Placebo | DRUG | Placebo comparator calculated volume to match active comparator inhaled or nebulized. |
Inclusion Criteria (Healthy Volunteers) 1. Females must be non-pregnant and non-lactating, and either surgically sterile or post-menopausal. 2. Males must be surgically sterile or, abstinent or, if engaged in sexual relations with a woman of child-bearing potential, the subject or the subject's non...
IONIS-ENaCRx is an investigational small molecule being studied for use in healthy subjects and patients with cystic fibrosis. It is in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being evaluated for safety, tolerability, pharmacokinetics, and pharmacodynamics.
IONIS-ENaCRx is being developed by Ionis Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol IONS. The company is conducting clinical trials to evaluate the drug's safety and effects in healthy volunteers and patients with cystic fibrosis.
IONIS-ENaCRx is in Phase 1 clinical development. A Phase 1/2a study has been completed, evaluating single and multiple doses in healthy volunteers and patients with cystic fibrosis. The drug remains investigational and is not yet approved for any use.
IONIS-ENaCRx has one completed clinical trial, NCT03647228, a Phase 1/2a study assessing safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses in healthy volunteers and patients with cystic fibrosis. The trial enrolled 98 participants in Germany and the United Kingdom.
IONIS-ENaCRx is the drug name as provided, with no alternative names listed. It is an investigational small molecule developed by Ionis Pharmaceuticals for respiratory conditions, specifically being studied in healthy subjects and patients with cystic fibrosis.